CMR Naviscan Announces the European Radiology Journal Publishes Data that Suggest Breast PET May Help to Identify with a High Degree of Sensitivity and Specificity

Share Article

CMR Naviscan announces that the European Radiology Journal publishes data that suggest that Breast PET, also known as Positron Emission Mammography (PEM), may help to identify, with a high degree of Sensitivity and Specificity, clinically significant breast cancer in women with suspicious calcifications on mammography.

European Radiology, the Journal of the European Society of Radiology, published results of a clinical study that concluded that Breast PET was able to identify all invasive carcinomas and high-grade DCIS in the presented sample, suggesting that this method may be useful for further evaluation of patients with suspected microcalcifications. Breast PET was found to have a sensitivity of 93.3%, Specificity of 96.0% and accuracy of 95%.    

Researchers found it advantageous that Breast PET images are acquired in the same projections as mammography, making it easy to compare both studies and confirm with confidence if there is increased glucose metabolism in the topography of the suspicious calcifications. Since positioning on Breast PET uses gentle immobilization instead of the breast compression used in mammography, side -by-side analysis was used to compare both methods.

The study was conducted at the A C Camargo Cancer Center – Department of Imaging, Sao Paolo, Brazil, and the final publication is available at

“Since PEM has a high sensitivity and specificity for the diagnosis of small breast cancers, including DCIS, it is reasonable to think that this functional method can improve the evaluation of suspicious findings at mammography, helping to avoid unnecessary biopsies,” said Almir G. V. Bitencourt, Principal Investigator of the study.

About CMR Naviscan

CMR Naviscan is a leader in organ-specific molecular imaging and part of the  Compañía Mexicana de Radiología CGR, S.A. de C.V.  (CMR) family of companies.  CMR is a major developer and manufacturer of high quality diagnostic imaging equipment that contributes to healthcare improvements through a technological innovation framework.  This includes the conversion, storage, processing and distribution of diagnostic imaging in digital form.  CMR Naviscan is headquartered in Carlsbad, California, is US FDA registered and ISO 13485:2012 certified.  Our flag ship product, the Solo II™ High Resolution Breast PET scanner, detects breast cancers as small as 1.6 mm.  Solo II is the industry leader in terms of its sensitivity and specificity in characterizing the extent and location(s) of previously diagnosed breast cancers.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Larry Ortiz
since: 11/2015
Follow >
Visit website